INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER

顺铂/卡铂和 FUDR 腹膜内治疗卵巢癌

• 批准号: 6277031
• 负责人: FRANCO MUGGIA
• 金额: $ 2.03万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6277031
• 关键词: carboplatin; cis platinum compound; clinical research; combination chemotherapy; female; floxuridine; human subject; human therapy evaluation; injection /infusion; neoplasm /cancer chemotherapy; ovary neoplasms; peritoneal cavity

Standard treatment of stage-III and -IV ovarian cancer has been surgical resection followed by intravenous paclitaxel and a platinum compound, which stops progression in 80% and results in negative findings in 20% of patients at Rsecond-lookS surgery. When residual disease is detected, therapy is less clear. In pilot studies, intraperitoneal (IP) floxuridine (FUdR) and cisplatin showed encouraging results. Subjects to be entered will be those who have completed stage-I chemotherapy for ovarian cancer but at Rsecond-lookS surgery have 2 1 cm peritoneal disease. IP catheters will be placed. FUdR (3g) will be given IP for 3 days, and cisplatin (60 mg/m2) will be given IP on the third day. (When applicable, carboplatin [500 ml] may follow immediately after FUdR.) This treatment cycle will be repeated every 3 weeks. Total duration of treatment will consist of 6 consecutive cycles as long as there is no progression or intolerable toxicity. Subjects will be assessed with a CT scan of the abdomen with IP contrast 6 weeks and one year after therapy or whenever recurrence is suspected.

III 期和 IV 期卵巢癌的标准治疗方法是手术 切除后静脉注射紫杉醇和铂化合物， 80% 的患者可停止进展，20% 的患者可得到阴性结果 接受 Rsecond-lookS 手术的患者人数。 当残留病 已检测到，治疗方法尚不明确。 在试点研究中，腹膜内 (IP) 氟尿苷 (FUdR) 和顺铂显示出令人鼓舞的结果。 科目 入选者为已完成 I 期化疗的患者 卵巢癌但在第二次检查时有 2 1 厘米腹膜 疾病。将放置 IP 导管。 FUdR (3g) 将获得 IP 3天，第三天IP顺铂（60mg/m2）。 （如果适用，卡铂 [500 毫升] 可能会在 FUdR.) 该治疗周期将每 3 周重复一次。 全部的 治疗持续时间将包括 6 个连续周期，只要 没有进展或无法忍受的毒性。 科目将是 通过腹部 CT 扫描和 IP 对比进行评估 6 周和 1 周 治疗后一年或怀疑复发时。